Conifer Point Pharmaceuticals

Conifer Point Pharmaceuticals was a private, pre-revenue biotechnology services and platform company founded in 2013 and headquartered in Cambridge, Massachusetts. It operated at the intersection of computational chemistry and drug discovery, providing tools and services to design, optimize, and strengthen the intellectual property of early-stage small molecule compounds. The company's business model centered on offering affordable computational drug design services to smaller biotechs and supporting its proprietary Boltzmann Maps platform. According to its website, Conifer Point was acquired by Lodo Therapeutics, marking the end of its operations as an independent entity.

Boltzmann Maps, a web application for drug design that uses computational tools for visualizing, designing, and prioritizing small molecules in pre-clinical discovery. The company also offered a suite of computational chemistry services for compound design, optimization, and IP analysis.

Conifer Point competed in the computational chemistry services and software market against large, established players like Charles River Laboratories (via its BioCelerate division) and Schrödinger, as well as numerous niche consultancies and a burgeoning field of AI/ML-driven drug discovery startups such as Atomwise and Recursion. Its differentiation was a focus on affordability and accessibility for small companies.